ClinicalTrials.gg
WithdrawnNCT05828277Updated Sep 26, 2023

A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

A Phase 1 interventional study of repotrectinib (TPX-0005) in Locally Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Turning Point Therapeutics, Inc.. Withdrawn at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Turning Point Therapeutics, Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Insufficient enrollment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.

Enrollment
43rd of 44
0 · median 66
Started
2022
with 2 others
Phase 1
16 of 50
none open now
Registered
46th of 50
by date

Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 43rd largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2022, is one of 16 in phase 1, and was the 46th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a Phase 1 study to evaluate the effect of moderate or severe hepatic impairment on the PK of repotrectinib in patients with advanced cancer.

Read the detailed description

This is a Phase 1, multicenter, multiple-dose, open-label, nonrandomized study to evaluate the effect of moderate or severe hepatic impairment on the PK of repotrectinib following single and multiple dose administration of repotrectinib in patients with advanced cancer. This study will enroll 8 patients each with moderate hepatic impairment, severe hepatic impairment and normal hepatic function.

03

Conditions studied

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or cytologically confirmed diagnosis of locally advanced or solid tumor for which standard curative or palliative measures do not exist or are no longer effective. In case of hepatocellular carcinoma, the diagnosis should be based on at least 1 of the following:

    1. The presence of at least 1 lesion, measuring ≥2 cm, with characteristic arterial enhancement and venous washout in the setting of liver cirrhosis and/or or C infection.
    2. The presence of liver lesion(s) (as defined in inclusion criteria 3a) with alphafetoprotein ≥ 400 ng/mL.
    3. Tissue confirmation.
  2. For patients with genetic ROS1 or NTRK 1-3 gene fusion, tissue-based local testing should be documented.
  3. Biliary obstruction for whom a biliary drain or stent has been placed are eligible.
  4. Performance Status scores 0 to 2.
  5. The patient must have no change in hepatic disease status within the last 30 days before screening.
  6. Patient with ascites must not have a paracentesis within 3 months of screening.
  7. Protocol specified baseline hematology and kidney function laboratory values

Key Exclusion Criteria:

  1. Concurrent participation in another therapeutic clinical study.
  2. Symptomatic or .
  3. Major surgery within 4 weeks.
  4. Clinically significant cardiovascular disease.
  5. History of non-pharmacologically induced prolonged corrected for heart rate interval.
  6. Known active infections requiring ongoing treatment (bacterial, fungal, or viral, including positivity).
  7. Gastrointestinal disease or other malabsorption syndromes.
  8. Current use or anticipated need for drugs that are known to be strong cytochrome P450 (CYP) 3A inhibitors or inducers.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Repotrectinib (TPX-0005)

    Oral repotrectinib (TPX-0005): Cohort 1: Patients with moderate hepatic impairment Cohort 2: Patients with severe hepatic impairment Cohort 3: Patients with normal hepatic function

    Drug: repotrectinib (TPX-0005)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC) of repotrectinib

    AUC0-t: Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration

    Time frame: Within 22 days of first repotrectinib dose

  2. Maximum Observed Plasma Concentration (Cmax) of repotrectinib

    Cmax: Evaluate the maximum plasma concentration

    Time frame: Within 22 days of first Repotrectinib dose

Secondary outcomes

  1. Evaluate safety and tolerability

    To evaluate the safety and tolerability of repotrectinib in patients with moderate and severe hepatic impairment and patients with normal hepatic function following single and multiple dose administration of repotrectinib assessed by CTCAE v5.0

    Time frame: 28 days after last dose of repotrectinib

07

Study locations

2 sites
  • Gabrail Cancer Research Center
    Canton, Ohio 44718, United States
  • Local Institution - 4103
    Madrid, 28033, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Aug 2025, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2023
First posted
Apr 25, 2023
StartActual
Jul 28, 2022
Primary completionEst.
Aug 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05828277
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Jul 28, 2022
Primary completion
Aug 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 26, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repotrectinib

Start the discussion